Author
Listed:
- Heng-Huan Lee
(The University of Texas MD Anderson Cancer Center)
- Ying-Nai Wang
(The University of Texas MD Anderson Cancer Center)
- Wen-Hao Yang
(The University of Texas MD Anderson Cancer Center
China Medical University)
- Weiya Xia
(The University of Texas MD Anderson Cancer Center)
- Yongkun Wei
(The University of Texas MD Anderson Cancer Center)
- Li-Chuan Chan
(The University of Texas MD Anderson Cancer Center)
- Yu-Han Wang
(The University of Texas MD Anderson Cancer Center
China Medical University)
- Zhou Jiang
(The University of Texas MD Anderson Cancer Center)
- Shouping Xu
(Harbin Medical University Cancer Hospital)
- Jun Yao
(The University of Texas MD Anderson Cancer Center)
- Yufan Qiu
(The University of Texas MD Anderson Cancer Center
Tianjin Medical University Cancer Institute and Hospital)
- Yi-Hsin Hsu
(The University of Texas MD Anderson Cancer Center)
- Wei-Lun Hwang
(National Yang Ming Chiao Tung University
National Yang-Ming University)
- Meisi Yan
(The University of Texas MD Anderson Cancer Center
Harbin Medical University)
- Jong-Ho Cha
(The University of Texas MD Anderson Cancer Center
College of Medicine, Inha University)
- Jennifer L. Hsu
(The University of Texas MD Anderson Cancer Center)
- Jia Shen
(The University of Texas MD Anderson Cancer Center)
- Yuanqing Ye
(The University of Texas MD Anderson Cancer Center)
- Xifeng Wu
(The University of Texas MD Anderson Cancer Center)
- Ming-Feng Hou
(Kaohsiung Medical University Hospital
Kaohsiung Medical University)
- Lin-Ming Tseng
(Taipei Veterans General Hospital
National Yang-Ming University)
- Shao-Chun Wang
(China Medical University)
- Mei-Ren Pan
(Kaohsiung Medical University)
- Chin-Hua Yang
(Taipei Veterans General Hospital)
- Yuan-Liang Wang
(China Medical University)
- Hirohito Yamaguchi
(The University of Texas MD Anderson Cancer Center
China Medical University)
- Da Pang
(Harbin Medical University Cancer Hospital)
- Gabriel N. Hortobagyi
(The University of Texas MD Anderson Cancer Center)
- Dihua Yu
(The University of Texas MD Anderson Cancer Center)
- Mien-Chie Hung
(The University of Texas MD Anderson Cancer Center
China Medical University
Asia University)
Abstract
Human ribonuclease 1 (hRNase 1) is critical to extracellular RNA clearance and innate immunity to achieve homeostasis and host defense; however, whether it plays a role in cancer remains elusive. Here, we demonstrate that hRNase 1, independently of its ribonucleolytic activity, enriches the stem-like cell population and enhances the tumor-initiating ability of breast cancer cells. Specifically, secretory hRNase 1 binds to and activates the tyrosine kinase receptor ephrin A4 (EphA4) signaling to promote breast tumor initiation in an autocrine/paracrine manner, which is distinct from the classical EphA4-ephrin juxtacrine signaling through contact-dependent cell-cell communication. In addition, analysis of human breast tumor tissue microarrays reveals a positive correlation between hRNase 1, EphA4 activation, and stem cell marker CD133. Notably, high hRNase 1 level in plasma samples is positively associated with EphA4 activation in tumor tissues from breast cancer patients, highlighting the pathological relevance of the hRNase 1-EphA4 axis in breast cancer. The discovery of hRNase 1 as a secretory ligand of EphA4 that enhances breast cancer stemness suggests a potential treatment strategy by inactivating the hRNase 1-EphA4 axis.
Suggested Citation
Heng-Huan Lee & Ying-Nai Wang & Wen-Hao Yang & Weiya Xia & Yongkun Wei & Li-Chuan Chan & Yu-Han Wang & Zhou Jiang & Shouping Xu & Jun Yao & Yufan Qiu & Yi-Hsin Hsu & Wei-Lun Hwang & Meisi Yan & Jong-H, 2021.
"Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation,"
Nature Communications, Nature, vol. 12(1), pages 1-18, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23075-2
DOI: 10.1038/s41467-021-23075-2
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23075-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.